• Je něco špatně v tomto záznamu ?

The Use of Artificial Intelligence in Pharmacovigilance: A Systematic Review of the Literature

M. Salas, J. Petracek, P. Yalamanchili, O. Aimer, D. Kasthuril, S. Dhingra, T. Junaid, T. Bostic

. 2022 ; 36 (5) : 295-306. [pub] 20220729

Jazyk angličtina Země Nový Zéland

Typ dokumentu systematický přehled

Perzistentní odkaz   https://www.medvik.cz/link/bmc22024310
E-zdroje Online Plný text

NLK ProQuest Central od 2008-05-01 do Před 1 rokem
Health & Medicine (ProQuest) od 2008-05-01 do Před 1 rokem

INTRODUCTION: Artificial intelligence through machine learning uses algorithms and prior learnings to make predictions. Recently, there has been interest to include more artificial intelligence in pharmacovigilance of products already in the market and pharmaceuticals in development. OBJECTIVE: The aim of this study was to identify and describe the uses of artificial intelligence in pharmacovigilance through a systematic literature review. METHODS: Embase and MEDLINE database searches were conducted for articles published from January 1, 2015 to July 9, 2021 using search terms such as 'pharmacovigilance,' 'patient safety,' 'artificial intelligence,' and 'machine learning' in the title or abstract. Scientific articles that contained information on the use of artificial intelligence in all modalities of patient safety or pharmacovigilance were reviewed and synthesized using a pre-specified data extraction template. Articles with incomplete information and letters to editor, notes, and commentaries were excluded. RESULTS: Sixty-six articles were identified for evaluation. Most relevant articles on artificial intelligence focused on machine learning, and it was used in patient safety in the identification of adverse drug events (ADEs) and adverse drug reactions (ADRs) (57.6%), processing safety reports (21.2%), extraction of drug-drug interactions (7.6%), identification of populations at high risk for drug toxicity or guidance for personalized care (7.6%), prediction of side effects (3.0%), simulation of clinical trials (1.5%), and integration of prediction uncertainties into diagnostic classifiers to increase patient safety (1.5%). Artificial intelligence has been used to identify safety signals through automated processes and training with machine learning models; however, the findings may not be generalizable given that there were different types of data included in each source. CONCLUSION: Artificial intelligence allows for the processing and analysis of large amounts of data and can be applied to various disease states. The automation and machine learning models can optimize pharmacovigilance processes and provide a more efficient way to analyze information relevant to safety, although more research is needed to identify if this optimization has an impact on the quality of safety analyses. It is expected that its use will increase in the near future, particularly with its role in the prediction of side effects and ADRs.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22024310
003      
CZ-PrNML
005      
20221031100455.0
007      
ta
008      
221017s2022 nz f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s40290-022-00441-z $2 doi
035    __
$a (PubMed)35904529
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a nz
100    1_
$a Salas, Maribel $u Daiichi Sankyo, Inc. & Center for Real-World Effectiveness and Safety of Therapeutics (CREST), University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, 211 Mount Airy Rd, Basking Ridge, NJ, USA $1 https://orcid.org/0000000156341558
245    14
$a The Use of Artificial Intelligence in Pharmacovigilance: A Systematic Review of the Literature / $c M. Salas, J. Petracek, P. Yalamanchili, O. Aimer, D. Kasthuril, S. Dhingra, T. Junaid, T. Bostic
520    9_
$a INTRODUCTION: Artificial intelligence through machine learning uses algorithms and prior learnings to make predictions. Recently, there has been interest to include more artificial intelligence in pharmacovigilance of products already in the market and pharmaceuticals in development. OBJECTIVE: The aim of this study was to identify and describe the uses of artificial intelligence in pharmacovigilance through a systematic literature review. METHODS: Embase and MEDLINE database searches were conducted for articles published from January 1, 2015 to July 9, 2021 using search terms such as 'pharmacovigilance,' 'patient safety,' 'artificial intelligence,' and 'machine learning' in the title or abstract. Scientific articles that contained information on the use of artificial intelligence in all modalities of patient safety or pharmacovigilance were reviewed and synthesized using a pre-specified data extraction template. Articles with incomplete information and letters to editor, notes, and commentaries were excluded. RESULTS: Sixty-six articles were identified for evaluation. Most relevant articles on artificial intelligence focused on machine learning, and it was used in patient safety in the identification of adverse drug events (ADEs) and adverse drug reactions (ADRs) (57.6%), processing safety reports (21.2%), extraction of drug-drug interactions (7.6%), identification of populations at high risk for drug toxicity or guidance for personalized care (7.6%), prediction of side effects (3.0%), simulation of clinical trials (1.5%), and integration of prediction uncertainties into diagnostic classifiers to increase patient safety (1.5%). Artificial intelligence has been used to identify safety signals through automated processes and training with machine learning models; however, the findings may not be generalizable given that there were different types of data included in each source. CONCLUSION: Artificial intelligence allows for the processing and analysis of large amounts of data and can be applied to various disease states. The automation and machine learning models can optimize pharmacovigilance processes and provide a more efficient way to analyze information relevant to safety, although more research is needed to identify if this optimization has an impact on the quality of safety analyses. It is expected that its use will increase in the near future, particularly with its role in the prediction of side effects and ADRs.
650    _2
$a umělá inteligence $7 D001185
650    12
$a nežádoucí účinky léčiv $x epidemiologie $7 D064420
650    _2
$a lidé $7 D006801
650    _2
$a strojové učení $7 D000069550
650    _2
$a léčivé přípravky $7 D004364
650    12
$a farmakovigilance $7 D060735
655    _2
$a systematický přehled $7 D000078182
700    1_
$a Petracek, Jan $u Institute of Pharmacovigilance, Hvezdova 2b, 14000, Prague, Czech Republic $1 https://orcid.org/0000000308060879
700    1_
$a Yalamanchili, Priyanka $u Daiichi Sankyo, Inc. & Rutgers University, 211 Mount Airy Rd, Basking Ridge, NJ, USA. pyalamanchi@dsi.com $1 https://orcid.org/0000000252908665
700    1_
$a Aimer, Omar $u Innovigilance, Laval, QC, Canada $1 https://orcid.org/000000020874486X
700    1_
$a Kasthuril, Dinesh $u Labcorp Drug Development, Princeton, NJ, USA
700    1_
$a Dhingra, Sameer $u Department of Pharmacy Practice, National Institute of Pharmaceutical Education and Research (NIPER), Hajipur, India $1 https://orcid.org/0000000325378889
700    1_
$a Junaid, Toluwalope $u Syneos Health, Morrisville, NC, USA $1 https://orcid.org/0000000330974159
700    1_
$a Bostic, Tina $u PPD, part of Thermo Fisher Scientific, Wilmington, NC, USA $1 https://orcid.org/000000017358851X
773    0_
$w MED00209774 $t Pharmaceutical medicine $x 1179-1993 $g Roč. 36, č. 5 (2022), s. 295-306
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35904529 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20221017 $b ABA008
991    __
$a 20221031100453 $b ABA008
999    __
$a ok $b bmc $g 1854182 $s 1175600
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 36 $c 5 $d 295-306 $e 20220729 $i 1179-1993 $m Pharmaceutical medicine $n Pharmaceut Med $x MED00209774
LZP    __
$a Pubmed-20221017

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...